Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
BMC Cancer
|
January 28, 2025
Rationale and design of APOLLO: a personalized rehAbilitation PrOgram in aLLOgeneic bone marrow transplantation
Edith Pituskin, Stephen Foulkes, Rachel J Skow, et al.
Leukemia & Lymphoma
|
November 9, 2024
Improvement in quality of life in MDS patients who become transfusion independent after treatment
Bo A Wan, Shabbir M H Alibhai, Lisa Chodirker, et al.
Leukemia
|
August 29, 2020
Revised 15-item MDS-specific frailty scale maintains prognostic potential
Bo A Wan, Aziz Nazha, Rebecca Starkman, et al.
Future Oncology (London, England)
|
March 7, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
American Journal of Hematology
|
July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems
Rena Buckstein, Enrico Balleari, Richard Wells, et al.
The Lancet. Haematology
|
December 22, 2023
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
BMC Cancer
|
January 28, 2025
Rationale and design of APOLLO: a personalized rehAbilitation PrOgram in aLLOgeneic bone marrow transplantation
Edith Pituskin, Stephen Foulkes, Rachel J Skow, et al.
Leukemia & Lymphoma
|
November 9, 2024
Improvement in quality of life in MDS patients who become transfusion independent after treatment
Bo A Wan, Shabbir M H Alibhai, Lisa Chodirker, et al.
Leukemia
|
August 29, 2020
Revised 15-item MDS-specific frailty scale maintains prognostic potential
Bo A Wan, Aziz Nazha, Rebecca Starkman, et al.
Future Oncology (London, England)
|
March 7, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
American Journal of Hematology
|
July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems
Rena Buckstein, Enrico Balleari, Richard Wells, et al.
The Lancet. Haematology
|
December 22, 2023
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, et al.
Page
of 3